A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)

NCT02497001 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1902

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: BGF MDI 320/14.4/9.6 μg
DRUG: GFF MDI (PT003) 14.4/9.6 μg
DRUG: BFF MDI (PT009) 320/9.6 μg
DRUG: Symbicort® Turbuhaler® (TBH) Inhalation Powder

Sponsor

Pearl Therapeutics, Inc.